Trial Profile
A Phase I, Non-randomized, Open-label, Fixed-sequence Study to Investigate the Effect of a Probe CYP3A4 Inhibitor and Inducer on the Pharmacokinetics of BAY1841788 (ODM 201) in Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Darolutamide (Primary) ; Itraconazole; Rifampicin
- Indications Male breast cancer; Prostate cancer
- Focus Pharmacokinetics
- Sponsors Bayer
- 30 Sep 2019 Results assessing drug-drug interaction potential of Darolutamide in invitro and invivo studies published in the European Journal of Drug Metabolism and Pharmacokinetics
- 28 Jul 2017 Status changed from active, no longer recruiting to completed.
- 04 May 2017 Status changed from recruiting to active, no longer recruiting.